Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Stock Chart & Stats
$5.98
-$0.47(-4.69%)
At close: 4:00 PM EST
$5.98
-$0.47(-4.69%)
Day’s Range― - ―
52-Week Range$4.81 - $13.88
Previous Close$9.5
Volume184.55K
Average Volume (3M)657.06K
Market Cap
$1.39M
Enterprise ValueN/A
Total Cash (Recent Filing)$136.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Nov 13, 2025EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding23,590,025
10 Day Avg. Volume589,716
30 Day Avg. Volume657,064
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.62
Price to Sales (P/S)0.00
P/FCF Ratio-2.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$86.33Price Target Upside1343.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCYB004 Phase 2a enrollment is complete, and top-line data is expected soon, indicating progress in late-stage programs.
Commercial ScalabilityManagement highlighted CYB004’s intramuscular protocol as scalable and commercially viable, offering operational advantages over longer-duration psychedelics.
Treatment EfficacyCYB003 demonstrated durable efficacy in major depressive disorder, with a significant reduction in depression scores and high remission rates.
Bears Say
Regulatory ExpectationsThe FDA is expected to evaluate the 6-month durability of effect for CYB003 in major depressive disorder, creating uncertainty.
Valuation ConcernsCYBN does not currently ascribe any value to CYB004 for generalized anxiety disorder, as it is not reflected in the stock valuation.
Cybin News
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $4.81 and its highest was $13.88 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.39M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Nov 13, 2025 which is in 3 days.
How were Cybin’s earnings last quarter?
Currently, no data Available
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.95.
How many shares outstanding does Cybin have?
Cybin has 23,590,025 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
Company Description
Cybin
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
CYBN Stock 12 Month Forecast
Average Price Target
$86.33
▲(1343.65% Upside)